SimonMed Imaging, one of the largest outpatient imaging providers in the US, announced it has completed the implementation of its third generation breast artificial intelligence (AI) program with ProFound AI 3.0 from iCAD. This FDA approved software further increases the sensitivity in detecting early breast cancer on 3D mammograms.
ProFound AI Version 3.0 was developed using over five million images from 30,000 cases, including almost 8,000 biopsy-proven cancers, and validated on approximately one million images from 3,500 cases that included 1,200 biopsy-proven cancers.
According to Dr. John Simon, Founder and CEO of SimonMed, “We have been a leader in adopting AI as well as 3D mammography and 3D breast ultrasound to use technology to better detect early breast cancer. Published studies as well as our own internal research has demonstrated that iCAD ProFound AI significantly improves early cancer detection. We are now on our third generation and the technology just gets better so now have better more sensitive AI and results in seconds.”
Also Read: MARS’s Spectral Imaging Photon Counting Point-of-Care CT Scanner System
Dr. Simon went on say, “Our commitment is bringing better technology to patients and this means that we do not charge extra for it unlike other providers that are asking patients to pay $60 or more. We know that many patients cannot afford this added expense and want all our patients to benefit from this lifesaving technology.”
SimonMed Imaging and iCAD have been collaboration partners for many years through the development of the first, second and now third generation of artificial intelligence imaging in the detection of early breast cancer.
SOURCE: PRNewswire